Kensana Health Lands $120 Million From GEM, Fueling a Global Plant Based Medicine Revolution
Kensana Health Inc. recently announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS, a…
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL for the Treatment of Hypercholesterolemia
Esperion recently announced Otsuka Pharmaceutical Co., Ltd., the Company’s partner for the development and commercialization of NEXLETOL (bempedoic acid) tablets in Japan, has received approval…
Alvotech Announces Marketing Approval of Three New Biosimilars
Alvotech recently announced its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received marketing approval for three new biosimilars from the Japanese Ministry of…
Deciphera Receives European Commission Approval of ROMVIMZA for the Treatment of Tenosynovial Giant Cell Tumor
Ono Pharmaceutical Co., Ltd. recently announced the European Commission (EC) has approved ROMVIMZA (vimseltinib) in the European Union (EU) for the treatment of adult patients…
Kindeva Opens New UK HQ & Manufacturing Site for the Development of Next-Generation Propellants
Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough. The…
CPHI Frankfurt Pharma Awards 2025 Finalists Announced
Hundreds of entries received across 14 categories showcasing innovation, sustainability, and leadership in pharma Informa Markets, recently announced the shortlist for the CPHI Pharma Awards…
Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study of LP-10 in Oral Lichen Planus
Lipella Pharmaceuticals Inc. recently announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in…
Cellares Selects Five Best-in-Class Technology Providers to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), recently announced multiple strategic technology partnerships to advance the Cell Q, the first fully automated quality…
Gerresheimer Expands Collaboration With Portal Instruments for Commercialization of the PRIME Nexus Reusable Autoinjector
Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries today announced that it will further expand…
Amphista Therapeutics Discloses First Details of SMARCA2 Degrader Program
Amphista Therapeutics recently disclosed first data on its SMARCA2 program including demonstrating exquisite selectivity of its sequentially bifunctional Targeted Glues for SMARCA2 over the closely…
Roivant & Priovant Announce Positive Phase 3 Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis
Roivant and Priovant Therapeutics recently announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). On the primary endpoint, brepocitinib 30…
Pneumagen Launches NeumoBind Technology Platform to Unlock New Opportunities in Intranasal Therapeutics
Pneumagen, a clinical-stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections, announces a…
Rein Therapeutics Announces New Translational Data on its Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press.…
Arch Strengthens its Position as a Leading Kidney Therapeutics Company With Acquisition of Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease
Arch Biopartners Inc. recently announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). The platform includes recently filed…
Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing, has announced a $20 million investment in its autoinjector and pen assembly,…
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate
Osivax recently announced the first participant has been vaccinated in its Phase 2b clinical trial (NCT05569239) evaluating OVX836, the company’s broad-spectrum influenza A vaccine candidate.…
Terumo Blood & Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America
In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo…
Areteia Therapeutics Announces Positive Topline Results From First Phase 3 Study of Oral Dexpramipexole in Eosinophilic Asthma
Areteia Therapeutics, Inc. recently announced positive results from the Phase 3 EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants…
FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers
FORE Biotherapeutics recently presented new plixorafenib results from the previously completed Phase 1/2a clinical trial that demonstrate treatment with plixorafenib in patients with BRAF-altered papillary…
Upperton Wins Pharma Contract Services Company of the Year at the Pharma Industry Awards UK 2025
Upperton Pharma Solutions has added another impressive award to a growing list of achievements, winning the award for Pharma Contract Services Company of the Year…
